Typical antipsychotics

Last updated: February 27, 2023

Typical antipsychotics

Psychiatric / Mental Health

Psychiatric / Mental Health

Antidepressants - Tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs): Nursing pharmacology
Disruptive, impulse control, and conduct disorders
Mood disorders: Clinical
Substance misuse and addiction: Clinical
Physical and sexual abuse
Child abuse: Clinical
Post-traumatic stress disorder
Trauma- and stressor-related disorders: Clinical
Dissociative disorders: Clinical
Dissociative disorders
Amnesia, dissociative disorders and delirium: Pathology review
Generalized anxiety disorder
Anxiety disorders: Clinical
Anxiety disorders: Nursing process (ADPIE)
Anxiety disorders, phobias and stress-related disorders: Pathology Review
Panic disorder
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants
Obsessive-compulsive disorder
Obsessive compulsive disorders: Clinical
Schizophrenia
Schizophrenia spectrum disorders: Clinical
Schizophrenia spectrum disorders: Pathology review
Schizophreniform disorder
Delusional disorder
Cluster A personality disorders
Cluster B personality disorders
Cluster C personality disorders
Schizoaffective disorder
Antipsychotics: Nursing pharmacology
Typical antipsychotics
Atypical antipsychotics
Neuroleptic malignant syndrome
Serotonin syndrome
Major depressive disorder
Suicide
Lithium
Mood disorders: Pathology review
Mood stabilizers: Nursing pharmacology
Personality disorders: Clinical
Personality disorders: Pathology review
Drug misuse, intoxication and withdrawal: Hallucinogens: Pathology review
Alcohol use disorder
Cocaine use disorder
Anticonvulsants and anxiolytics: Barbiturates
Psychomotor stimulants
Cannabis use disorder
Opioid use disorder
Toxidromes: Clinical
Eating disorders: Clinical
Eating disorders: Pathology review
Eating disorders: Nursing process (ADPIE)
Anorexia nervosa
Bulimia nervosa
Somatic symptom disorder
Somatic symptom disorders: Clinical
Malingering, factitious disorders and somatoform disorders: Pathology review
Factitious disorder
Neurodevelopmental disorders: Clinical
Learning disability
Autism spectrum disorder
Tourette syndrome
Movement disorders: Pathology review
Hyperkinetic movement disorders: Clinical
Elimination disorders: Clinical
Encopresis
Enuresis
ADHD: Information for patients and families (The Primary School)
Attention deficit hyperactivity disorder
Sympatholytics: Alpha-2 agonists
Disruptive, impulse-control and conduct disorders: Clinical
Delirium
Dementia and delirium: Clinical
Dementia: Pathology review
Alzheimer disease
Medications for Alzheimer disease: Nursing pharmacology
Vascular dementia
Creutzfeldt-Jakob disease
Parkinson disease
Parkinson disease: Nursing process (ADPIE)
Huntington disease
Wernicke-Korsakoff syndrome

Transcript

Watch video only

Antipsychotics, as their name implies, are mainly used to treat schizophrenia and other psychotic conditions. Even though the exact cause of schizophrenia is still unknown, there's some evidence that suggests it’s related to altered levels of the neurotransmitter dopamine. Now, antipsychotics are subdivided into two main categories: the first generation or typical antipsychotics, and the second generation or atypical antipsychotics.

Alright, within the brain, dopamine is found in 4 main dopamine pathways: the mesolimbic pathway, which controls motivation and desire; the mesocortical pathway, which helps regulate emotions; the nigrostriatal pathway, which contains motor neurons that bypass the medullary pyramids, to control involuntary movements and coordination; and lastly, the tuberoinfundibular pathway, which releases dopamine to limit the secretion of prolactin. Other regions of the central nervous system that are rich in dopamine receptors include the chemoreceptor trigger zone, which initiates the vomiting reflex, and the medullary periventricular pathway, which regulates eating behavior.

However, in schizophrenia, altered levels of dopamine mainly affect the mesolimbic pathway and mesocortical pathway. There’s usually high levels of dopamine in the mesolimbic pathway which cause positive symptoms of schizophrenia, such as delusions, hallucinations, and disorganized thought. On the other hand, low levels of dopamine in the mesocortical pathway cause negative symptoms of schizophrenia, such as lack of motivation, social withdrawal, and “flat affect,” which basically means a lack of emotions.

When it comes to treating schizophrenia, some typical antipsychotics like haloperidol, trifluoperazine, and fluphenazine have a higher potency, which means you need less of it to achieve a therapeutic effect. The lower potency antipsychotics include thioridazine and chlorpromazine and they require larger doses to achieve the same therapeutic effect as high-potency antipsychotics.

Now, in conditions such as schizophrenia, typical antipsychotics block dopamine D2 receptors in the mesolimbic pathway, which alleviates positive symptoms of schizophrenia. However, they also block dopamine receptors in the mesocortical pathway, which might actually worsen the negative symptoms.

Other psychiatric indications include psychosis, delirium, bipolar disorder, obsessive-compulsive disorder, Tourette syndrome, and Huntington disease. Aside from their use in psychiatric disorders, blocking dopamine receptors in the chemoreceptor trigger zone can also decrease nausea and vomiting, while blocking histamine H1 receptors can have an antipruritic and sedative effect.

Alright, moving on to side effects. In the tuberoinfundibular pathway, they stimulate the release of prolactin, causing oligomenorrhea, galactorrhea, and gynecomastia; and lastly, in the nigrostriatal pathway, they cause extrapyramidal symptoms, which usually involve abnormal movements.

Let’s start with dystonia, which can occur within a few hours to days of treatment, and includes muscle spasms of the tongue, face, neck, and back. It also causes oculogyric crisis, which is a spasm of the extraocular muscles, causing an upward and outward position of the eyes. After a few days to a month, there could be Akathisia or pseudoparkinsonism. Akathisia is characterized by restlessness and an urge to move the limbs. Pseudoparkinsonism is characterized by muscle rigidity, usually in the facial muscles, giving the face a wooden, mask-like appearance. Other symptoms include bradykinesia, or slow movements, and tremors. It’s important to note that typical antipsychotics are more likely to cause these side effects compared to the atypical antipsychotics. However, extrapyramidal symptoms usually disappear once the medication is stopped.

Now, moving on to tardive dyskinesia, which can present after several months or even years; is characterized by constant involuntary, rhythmic movements. This typically happens with the perioral muscles causing the person to repeatedly smack, or purse their lips. Unlike acute extrapyramidal symptoms, tardive dyskinesia can be irreversible, so the medication should be discontinued at the first sign of tardive dyskinesia.

Key Takeaways

Typical antipsychotics, also known as first-generation antipsychotics, are a class of medications used to treat various psychiatric disorders, particularly schizophrenia and other psychotic disorders. They work by blocking dopamine D2 receptors in the mesolimbic pathway in the brain, which helps to reduce the symptoms of psychosis.

Typical antipsychotics include medications such as chlorpromazine, haloperidol, and fluphenazine. These medications are generally effective at reducing positive symptoms of psychosis, such as hallucinations and delusions, but may have limited effectiveness for negative symptoms and may also cause significant side effects.

Common side effects of typical antipsychotics include extrapyramidal symptoms, such as tremors and muscle rigidity, as well as weight gain, sedation, and sexual dysfunction. Long-term use of these medications may also be associated with a higher risk of developing tardive dyskinesia, a movement disorder characterized by involuntary muscle movements.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Neuroleptic Malignant Syndrome" Annals of Pharmacotherapy (2016)
  5. "Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis" The Lancet (2009)
  6. "Update on Typical and Atypical Antipsychotic Drugs" Annual Review of Medicine (2013)